Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.44 |
| ▸ | CETP | P11597 | 2/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390062 | 0.90 | GPR119 (0.47) | GPR119CETPTBK1EPHA2KDR | |
| SCHEMBL390006 | 0.90 | GPR119 (0.47) | GPR119CETPTBK1EPHA2KDR | |
| SCHEMBL10090600 | 0.88 | GPR119 (0.45) | GPR119CETPTBK1EPHA2KDR | |
| SCHEMBL389862 | 0.88 | GPR119 (0.46) | GPR119CETPTBK1EPHA2KDR | |
| SCHEMBL387449 | 0.87 | GPR119 (0.45) | GPR119CETPTBK1EPHA2KDR | |
| SCHEMBL4167778 | 0.86 | GPR119 (0.43) | GPR119CETPTBK1EPHA2KDR | |
| SCHEMBL389716 | 0.86 | GPR119 (0.48) | GPR119CETPTBK1EPHA2KDR | |
| SCHEMBL392191 | 0.85 | GPR119 (0.47) | GPR119CETPTBK1EPHA2KDR | |
| SCHEMBL389991 | 0.84 | GPR119 (0.47) | GPR119CETPTBK1 | |
| SCHEMBL4167177 | 0.82 | GPR119 (0.45) | GPR119CETPTBK1EPHA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193359-B2 | G-protein coupled receptor agonists | PROSIDION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1838706-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006067532-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LTD (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | GPR119, GPR65, GPR84 | GPR119 1/4885CETP 886/4885TBK1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.